Blood Adv. 2024 May 28;8(10):2573-2574. doi: 10.1182/bloodadvances.2024012705.
NO ABSTRACT
PMID:38805218 | DOI:10.1182/bloodadvances.2024012705
Recent Content
- Cadonilimab combo boosts survival in advanced pancreatic cancer patients
- Risk for second primary malignancies in patients with multiple myeloma: a systematic review and meta-analysis
- New targeted therapy Ojemda approved in EU for pediatric glioma
- Mapping the Landscape of Quality of Life in Smoldering Multiple Myeloma Clinical Trials: A Systematic Review
- Mo-Rez shows strong early responses in ovarian, endometrial cancers
- FDA grants fast track status to oral therapy for hard-to-treat myeloma
- Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial
- Concordance and prognostic value of bone-marrow MRD and PET-CT in multiple myeloma: a systematic review and meta-analysis
- Advocacy group marks AML Awareness Day with interactive webpage launch
- Daraxonrasib may offer new hope in previously treated pancreatic cancer